These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 16580903)

  • 1. Comparison of midazolam and simvastatin as cytochrome P450 3A probes.
    Chung E; Nafziger AN; Kazierad DJ; Bertino JS
    Clin Pharmacol Ther; 2006 Apr; 79(4):350-61. PubMed ID: 16580903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam.
    Chaobal HN; Kharasch ED
    Clin Pharmacol Ther; 2005 Nov; 78(5):529-39. PubMed ID: 16321619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
    Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
    Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
    Kharasch ED; Walker A; Hoffer C; Sheffels P
    Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
    Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ
    Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping.
    Lee JI; Chaves-Gnecco D; Amico JA; Kroboth PD; Wilson JW; Frye RF
    Clin Pharmacol Ther; 2002 Dec; 72(6):718-28. PubMed ID: 12496753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam.
    Masica AL; Mayo G; Wilkinson GR
    Clin Pharmacol Ther; 2004 Oct; 76(4):341-9. PubMed ID: 15470333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam.
    Chen M; Nafziger AN; Bertino JS
    Drug Metab Dispos; 2006 Dec; 34(12):2079-82. PubMed ID: 16997909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity.
    Kharasch ED; Walker A; Hoffer C; Sheffels P
    J Clin Pharmacol; 2005 Oct; 45(10):1187-97. PubMed ID: 16172184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects.
    Dresser GK; Schwarz UI; Wilkinson GR; Kim RB
    Clin Pharmacol Ther; 2003 Jan; 73(1):41-50. PubMed ID: 12545142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo.
    Gorski JC; Huang SM; Pinto A; Hamman MA; Hilligoss JK; Zaheer NA; Desai M; Miller M; Hall SD
    Clin Pharmacol Ther; 2004 Jan; 75(1):89-100. PubMed ID: 14749695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of simultaneous induction and inhibition of CYP3A by St John's Wort and ritonavir on CYP3A activity.
    Hafner V; Jäger M; Matthée AK; Ding R; Burhenne J; Haefeli WE; Mikus G
    Clin Pharmacol Ther; 2010 Feb; 87(2):191-6. PubMed ID: 19924124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Drug-Drug Interaction Study to Evaluate the Effect of TAS-303 on CYP3A Activity in the Small Intestine and Liver.
    Kumagai Y; Fujita T; Maeda M; Sasaki Y; Nagaoka M; Huang J; Takenaka T; Kawai M
    J Clin Pharmacol; 2020 Jun; 60(6):702-710. PubMed ID: 32026490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone.
    Kharasch ED; Hoffer C; Whittington D; Sheffels P
    Clin Pharmacol Ther; 2004 Sep; 76(3):250-69. PubMed ID: 15371986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ketoconazole renders poor CYP3A phenotype status with midazolam as probe drug.
    Tham LS; Lee HS; Wang L; Yong WP; Fan L; Ong AB; Sukri N; Soo R; Lee SC; Goh BC
    Ther Drug Monit; 2006 Apr; 28(2):255-61. PubMed ID: 16628140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity.
    Kurnik D; Wood AJ; Wilkinson GR
    Clin Pharmacol Ther; 2006 Sep; 80(3):228-34. PubMed ID: 16952489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of the treatment period with erythromycin on cytochrome P450 3A activity in humans.
    Okudaira T; Kotegawa T; Imai H; Tsutsumi K; Nakano S; Ohashi K
    J Clin Pharmacol; 2007 Jul; 47(7):871-6. PubMed ID: 17585116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duration of pleconaril effect on cytochrome P450 3A activity in healthy adults using the oral biomarker midazolam.
    Ma JD; Nafziger AN; Rhodes G; Liu S; Bertino JS
    Drug Metab Dispos; 2006 May; 34(5):783-5. PubMed ID: 16467135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam.
    Saari TI; Laine K; Leino K; Valtonen M; Neuvonen PJ; Olkkola KT
    Clin Pharmacol Ther; 2006 Apr; 79(4):362-70. PubMed ID: 16580904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low hepatic cytochrome P450 3A activity is a risk for corticosteroid-induced osteonecrosis.
    Kaneshiro Y; Oda Y; Iwakiri K; Masada T; Iwaki H; Hirota Y; Kondo K; Takaoka K
    Clin Pharmacol Ther; 2006 Oct; 80(4):396-402. PubMed ID: 17015057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.